Publications

  1. Duchnowska R, Szczylik C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 2005; 31: 312-18. IF: 4.549.

  2. Duchnowska R. Novus ordo seclorum. New applications of monoclonal antibodies in breast cancer. Contemporary Oncology 2005; 9: 424-428.

  3. Duchnowska R, Szczylik C. Central nervous system metastases in advanced breast cancer patients treated with trastuzumab. Contemporary Oncology 2006; 10:51-56.

  4. Duchnowska R. EGFR tyrosine kinase inhibitors in the treatment of brain metastases in non-small cell lung cancer. Onkol Prakt Klin 2009; 5: 92-98.

  5. Duchnowska R, Dziadziuszko R, Czartoryska-Arłukowicz B, Radecka B, Szostakiewicz B, Sosińska-Mielcarek K, Karpińska A, Starosławska E, Kubiatowski T, Szczylik C. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009; 117:297-303.

  6. Steger GG, Abrahámová J, Bacanu F, Brincat S, Brize A, Cesas A, Cufer T, Dank M, Duchnowska R, Eniu A, Jassem J, Kahán Z, Matos E, Padrik P, Plāte S, Pokker H, Purkalne G, Timcheva C, Tzekova V, Vyzula R, Zielinski CC. Current standards in the treatment of metastatic breast cancer with focus on lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr. 2010; 122:368-79.

  7. Duchnowska R. Central nervous system metastases during anti-HER2 therapy in breast cancer. Onkol Prakt Klin 2010; 10:272-277.

  8. Duchnowska R. Lapatinib in the treatment of advanced HER2-positive breast cancer patients with brain metastases. Onkol Prakt Klin 2011; 7, suppl. D: D6–D9.

  9. Preusser M, Winkler F, Collette L, Haller S, Marreaud S, Soffietti R, Klein M, Reijneveld JC, Tonn JC, Baumert BG, Mulvenna P, Schadendorf D, Duchnowska R, Berghoff AS, Lin N, Cameron DA, Belkacemi Y, Jassem J, Weber DC. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer 2012;48:3439-3447.

  10. Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, Paquet A, Lie Y, Czartoryska-Arłukowicz M, Wysocki P, Jankowski T, Radecka B, Foszczyńska-Kłoda M, Litwiniuk M, Dębska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J. Correlation between quantitative HER2 protein expression and risk of brain metastases in HER2-positive advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist 2012;17:26-35.

  11. Duchnowska R, Dziadziuszko R, Trojanowski T, Mandat T, Och W, Czartoryska-Arłukowicz B, Radecka B, Olszewski W, Szubstarski F, Kozłowski W, Jarosz B, Rogowski W, Kowalczyk A, Limon J, Biernat W, Jassem J, for the Polish Brain Metastasis Consortium. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res 2012 16;14:R119.

  12. Sosińska-Mielcarek K, Duchnowska R, Winczura P, Badzio A, Majewska H, Lakomy J, Pęksa R, Pieczyńska B, Radecka B, Dębska S, Biernat W, Jassem J. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51. Breast 2013; 22:1178-83.

  13. Duchnowska R, Miciuk B, Bodnar R, Waśniewski L, Szczylik C. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib. J Oncol Pharm Pract 2012;19:186-189.

  14. Woditschka S, Evans L, Duchnowska R, Reed LT, Palmieri D, Qian Y, Badve S,Sledge G Jr, Gril B, Aladjem MI, Fu H, Flores NM, Gökmen-Polar Y, Biernat W, Szutowicz-Zielińska E, Mandat T, Trojanowski T, Och W, Czartoryska-Arlukowicz B, Jassem J, Mitchell JB, Steeg PS. DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. J Natl Cancer Inst. 2014 Jun 19;106 (7).

  15. Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat W, Jassem J. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff. Clin Cancer Res. 2014; 20: 2805-13

  16. Palmieri D, Duchnowska R, Woditschka S, Hua E, Qian Y, Biernat W, Sosińska-Mielcarek K, Gril B, Stark AM, Hewitt SM, Liewehr DJ, Steinberg SM, Jassem J, Steeg PS. Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin Cancer Res. 2014; 20: 2727-39.

  17. Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat W, Jassem J. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab:independent validation of the p95HER2 clinical cutoff. Clin Cancer Res. 2014 May 15;20(10):2805-13.

  18. Woditschka S, Evans L, Duchnowska R, Reed LT, Palmieri D, Qian Y, Badve S, Sledge G Jr, Gril B, Aladjem MI, Fu H, Flores NM, Gökmen-Polar Y, Biernat W, Szutowicz-Zielińska E, Mandat T, Trojanowski T, Och W, Czartoryska-Arlukowicz B, Jassem J, Mitchell JB, Steeg PS. DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. J Natl Cancer Inst. 2014 Jun 19;106(7).

  19. Duchnowska R, Jassem J, Goswami CP, Dundar M, Gökmen-Polar Y, Li L, Woditschka S, Biernat W, Sosińska Mielcarek K, Czartoryska-Arłukowicz B, Radecka B, Tomasevic Z, Stępniak P, Wojdan K, Sledge GW Jr, Steeg PS, Badve S. Predicting early brain metastases based on clinicopathological factors and gene expressionanalysis in advanced HER2-positive breast cancer patients. J Neurooncol. 2015 Mar;122(1):205-16.

  20. Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, Haddad M, Paquet A, Lie Y, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arłukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Biernat W, Jassem J. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol. 2015 Feb 13.pii: nov012.

  21. Duchnowska R, Wysocki PJ, Korski K, Czartoryska-Arłukowicz B, Niwińska A, Orlikowska M, Radecka B, Studziński M, Demlova R, Ziółkowska B, Merdalska M, Hajac Ł, Myśliwiec P, Zuziak D, Dębska-Szmich S, Lang I, Foszczyńska-Kłoda M, Karczmarek-Borowska B, Żawrocki A, Kowalczyk A, Biernat W, Jassem J; Central and East European Oncology Group (CEEOG). Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. Oncotarget. 2016 Jan 5;7(1):550-64.

  22. Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, Czartoryska-Arłukowicz B, Olszewski WP, Och W, Kalinka-Warzocha E, Kozłowski W, Kowalczyk A, Loi S, Biernat W, Jassem J; Polish Brain Metastasis Consortium. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 2016 Apr 27;18(1):43.

  23. Duchnowska R, Jarząb M, Żebracka-Gala J, Matkowski R, Kowalczyk A, Radecka B, Kowalska M, Pfeifer A, Foszczyńska-Kłoda M, Musolino A, Czartoryska-Arłukowicz B, Litwiniuk M, Surus-Hyla A, Szabłowska-Siwik S, Karczmarek-Borowska B, Dębska-Szmich S, Głodek-Sutek B, Sosińska-Mielcarek K, Chmielowska E, Kalinka-Warzocha E, Olszewski WP, Patera J, Żawrocki A, Pliszka A, Tyszkiewicz T, Rusinek D, Oczko-Wojciechowska M, Jassem J, Biernat W; Polish Brain Metastasis Consortium.. Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer. Clin Breast Cancer. 2016 Sep 8. pii: S1526-8209(16)30238-5.

  24. Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, Palmieri D, Liewehr DJ, Steinberg SM, Kloc W, Izycka-Swieszewska E, Duchnowska R, Nayyar N, Brastianos PK, Steeg PS, Gril B. Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer. Clin Cancer Res. 2016 Nov 1;22(21):5287-5299.

  25. Jeong J, Audet R, Chang J, Wong H, Willis S, Young B, Edgerton S, Thor A, Sledge G, Duchnowska R, Jassem J, Adamowicz K, Leyland-Jones B, Shen C. A comparison between DASL and Affymetrix on probing the whole-transcriptome. Journal of the Korean Statistical Society 2016; 45: 149-155.

  26. Duchnowska R. Czy u chorych na HER2-dodatniego raka piersi z przerzutem do mózgu rozpoznanym w trakcie leczenia trastuzumabem należy zmienić lek? Głos na TAK. We should change the current treatment in HER2-positive breast cancer patients with brain metastases developed during trastuzumab administration. Nowotwory Journal of Oncology 2015;65(2):144-147.

  27. Duchnowska R, Rucińska M, Radecka B. Rola radioterapii i leczenia systemowego u chorych na lite nowotwory złośliwe z przerzutami do mózgu. Onkol. Dypl. 2015;4:24-32.

 

Contact

home
Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street
80-211 Gdańsk, Poland
 
email
Phone: +48 58 349 2282
Fax: +48 58 349 22 44
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.